نتائج البحث - "Hamm, John"

مستخلص: BACKGROUND: Targeting programmed cell death protein 1 (PD‐1) and indoleamine 2,3‐dioxygenase (IDO1) pathways is an appealing option for cancer treatment. METHODS: The open‐label, phase 1/2 ECHO‐203 study evaluated the safety, tolerability, and efficacy of the IDO1 inhibitor epacadostat in combination with durvalumab, a human anti–PD‐L1 monoclonal antibody in adult patients with advanced solid tumors. RESULTS: The most common treatment‐related adverse events were fatigue (30.7%), nausea (21.0%), decreased appetite (13.1%), pruritus (12.5%), maculopapular rash (10.8%), and diarrhea (10.2%). Objective response rate (ORR) in the overall phase 2 population was 12.0%. Higher ORR was observed in immune checkpoint inhibitor (CPI)‐naïve patients (16.1%) compared with patients who had received previous CPI (4.1%). Epacadostat pharmacodynamics were evaluated by comparing baseline kynurenine levels with those on therapy at various time points. Only the 300‐mg epacadostat dose showed evidence of kynurenine modulation, albeit unsustained. CONCLUSIONS: Epacadostat plus durvalumab was generally well tolerated in patients with advanced solid tumors. ORR was low, and evaluation of kynurenine concentration from baseline to cycle 2, day 1, and cycle 5, day 1, suggested >300 mg epacadostat twice daily is needed to ensure sufficient drug effect. Clinical trial information: A study of epacadostat (INCB024360) in combination with durvalumab (MEDI4736) in subjects with selected advanced solid tumors (ECHO‐203) (NCT02318277). Epacadostat plus durvalumab was generally well tolerated in patients with advanced solid tumors. Objective response rate was low, and evaluation of kynurenine concentration from baseline to cycle 2, day 1, and cycle 5, day 1, suggested that >300 mg twice daily of epacadostat is needed to ensure sufficient drug effect. [ABSTRACT FROM AUTHOR]

: Copyright of Cancer (0008543X) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

النص الكامل

6

دورية أكاديمية

The Marshes of Mount Liang Beyond the Sea: Jin Yong's Early Martial Arts Fiction and Postwar Hong Kong

المؤلفون: Hamm, John Christopher

المصدر: Modern Chinese Literature and Culture, 1999 Apr 01. 11(1), 93-123.

الوصول الحر: https://www.jstor.org/stable/41490792Test

7

دورية أكاديمية

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).

المؤلفون: Geyer Jr., Charles E., Bandos, Hanna, Rastogi, Priya, Jacobs, Samuel A., Robidoux, André, Fehrenbacher, Louis, Ward, Patrick J., Polikoff, Jonathan, Brufsky, Adam M., Provencher, Louise, Paterson, Alexander H. G., Hamm, John T., Carolla, Robert L., Baez-Diaz, Luis, Julian, Thomas B., Swain, Sandra M., Mamounas, Eleftherios P., Wolmark, Norman

المصدر: Breast Cancer Research & Treatment; Jun2022, Vol. 193 Issue 3, p555-564, 10p

مستخلص: Purpose: Results from adjuvant trials evaluating 6 cycles of epirubicin-based chemotherapy regimens suggested these programs may be more effective than 4 cycles of doxorubicin-based chemotherapy. Method: NSABP B-36 was a phase III clinical trial originally designed as a 2 × 2 factorial study comparing 6 cycles of 5-FU, epirubicin, and cyclophosphamide (FEC-100) to 4 cycles of conventional doxorubicin and cyclophosphamide (AC) with celecoxib or placebo. Shortly after activation, concerns regarding increased cardiovascular risks among selective COX-2 inhibitors resulted in a decision to remove the celecoxib/placebo from the trial. Women with histologically node-negative invasive breast cancer who had undergone primary surgery with a lumpectomy or total mastectomy were eligible. Primary endpoint was disease-free survival (DFS). Results: Between May 2004 and July 2008, 2722 patients were enrolled. Administration of FEC-100 did not result in improvement in DFS compared to AC (HR 1.09; 95% CI 0.92–1.29, p value = 0.31). The effect of FEC-100 compared to AC on DFS was significantly different for receptor-positive (HR 1.32, 95% CI 1.05–1.66) compared to receptor-negative patients (HR 0.86, 95% CI 0.66–1.11) (treatment-by-receptor status interaction p value = 0.02). There was no statistically significant difference in the effect of treatment on overall survival (OS) with FEC-100 compared to AC (HR 1.06; 95% CI 0.84–1.35, p value = 0.61). Overall, Grade 3 and 4 adverse events were more frequent in the FEC-100 group. Conclusion: The results of B-36 do not support use of six-cycle anthracycline-based regimens in node-negative breast cancer. Prolongation of anthracycline-based therapy with FEC-100 does not improve DFS or OS, relative to AC for 4 cycles, and was associated with expected increases in toxicity. A statistically significant interaction between treatment and hormone receptor status favoring AC in hormone-receptor-positive breast cancers is consistent with the hypothesis that optimal duration of chemotherapy may be four cycles in these patients. Late cardiac events and deaths prior to recurrence or second cancer were infrequent on both arms, but slightly higher with FEC-100. Trial registration: ClinicalTrials.gov: NCT00087178. [ABSTRACT FROM AUTHOR]

: Copyright of Breast Cancer Research & Treatment is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

8

مراجعة

“Did Phonocentrism Drive Modern Chinese Script Reform and Chinese Cultural Modernity?”

المؤلفون: Hamm, John Christopher, Handel, Zev

المصدر: China Review International, 2019 Jan 01. 26(1/2), 37-52.

العلاقة: Zhong Yurou Chinese Grammatology: Script Revolution and Literary Modernity, 1916–1958

الوصول الحر: https://www.jstor.org/stable/27044193Test

9

دورية أكاديمية

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.

المؤلفون: Ganz, Patricia A., Bandos, Hanna, Geyer Jr., Charles E., Robidoux, André, Paterson, Alexander H. G., Polikoff, Jonathan, Baez-Diaz, Luis, Brufsky, Adam M., Fehrenbacher, Louis, Parsons, Ann W., Ward, Patrick J., Provencher, Louise, Hamm, John T., Stella, Philip J., Carolla, Robert L., Margolese, Richard G., Shibata, Henry R., Perez, Edith A., Wolmark, Norman

المصدر: Breast Cancer Research & Treatment; Feb2022, Vol. 192 Issue 1, p153-161, 9p

مستخلص: Background: The NSABP B-36 compared four cycles of doxorubicin and cyclophosphamide (AC) with six cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC-100) in node-negative early-stage breast cancer. A sub-study within B-36, focusing on symptoms, quality of life (QOL), menstrual history (MH), and cardiac function (CF) was conducted. Patients and methods: Patients completed the QOL questionnaire at baseline, during treatment, and every 6 months through 36 months. FACT-B Trial Outcome Index (TOI), symptom severity, and SF-36 Vitality and Physical Functioning (PF) scales scores were compared between the two groups using a mixed model for repeated measures analysis. MH was collected at baseline and subsequently assessed if menstrual bleeding occurred within 12 months prior to randomization. Post-chemotherapy amenorrhea outcome was examined at 18 months and was defined as lack of menses in the preceding year. Logistic regression was used to test for association of amenorrhea and treatment. CF assessment was done at baseline and 12 months. Correlation analysis was used to address associations between changes in baseline and 12-month PF and concurrent CF changes measured by LVEF. Results: FEC-100 patients had statistically significantly lower TOI scores during chemotherapy (P = 0.02) and at 6 months (P < 0.001); lower Vitality score at 6 months (P < 0.01), and lower PF score during the first year than AC patients. There were no statistically significant QOL score differences between the two groups beyond 12 months. No significant differences in symptom severity between the two groups were observed. Rates of amenorrhea were significantly different between FEC-100 and AC (67.4% vs. 59.1%, P < 0.001). There was no association between changes in LVEF and PF (P = 0.38). Conclusions: Statistically significant QOL differences between the two groups favored AC; however, the magnitude was small and unlikely to be clinically meaningful. There was a clinical and statistically significant difference in risk for amenorrhea, favoring AC. Trial registry: NCT00087178; Date of registration: 07/08/2004. [ABSTRACT FROM AUTHOR]

: Copyright of Breast Cancer Research & Treatment is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

10

مراجعة

Sound Rising from the Paper: Nineteenth-Century Martial Arts Fiction and the Chinese Acoustic Imagination Paize Keulemans

المؤلفون: Hamm, John Christopher

المصدر: Harvard Journal of Asiatic Studies, 2016 Jun 01. 76(1/2), 237-249.

العلاقة: Sound Rising from the Paper: Nineteenth-Century Martial Arts Fiction and the Chinese Acoustic Imagination Paize Keulemans

الوصول الحر: https://www.jstor.org/stable/44478345Test

تنقيح النتائج